In vitro results demonstrate that mutant GlyRS binds to and activates Trk receptors A-C, and that the extent of variant binding correlates with the severity of the CMT2D phenotype observed in mice (Sleigh et al., 2017a). The gene discussed is GARS1; the disease is Charcot-Marie-Tooth disease type 2D.